Blood-Brain Barrier

In this video, Annick Desjardins, MD, professor of neurosurgery, professor of neurology and member of the Duke Cancer Institute, discusses monitoring patients following their initial treatment.

Results of an ongoing clinical trial showed that an oral, small molecule oligomer antagonist used to treat mild to moderate Alzheimer’s disease boosted connectivity between regions of the brain as a promising sign of cognitive improvement.

Bypassing the blood-brain barrier remains an obstacle for novel therapeutics. Healio spoke to Thomas Chen, MD, PhD, founder and CEO of NeOnc, to find out how a novel nasal spray formulation to treat brain cancer overcomes these challenges.

A French biotechnology company has announced a global license agreement with a California-based biotech firm to utilize the former’s platform technology for delivery of RNA-targeted therapeutics.

The FDA has cleared an investigational new drug application for an unmodified neural-derived exosome to treat those with acute ischemic stroke, according to its manufacturer.

Small HDL particles play a significant role in the prevention of Alzheimer’s disease, and an inherited gene present in one in four people hinders its production in the brain, increasing risk for cognitive decline, a speaker reported.

An Italian pharmaceutical company and a Boston-area biotechnology research firm announced a partnership to advance a novel blood-brain barrier-crossing platform technology for those with lysosomal storage disorders.

Today is Glioblastoma Awareness Day.

May is Brain Cancer Awareness Month.

The use of low-intensity pulsed ultrasound with concomitant administration of IV microbubbles can improve the delivery of albumin-bound paclitaxel and carboplatin through the blood-brain barrier, study results showed.